Dr Landgren on the Rationale for Assessing Daratumumab Plus KRd in Newly Identified Myeloma
“The background of this study was based on the fact that modern combination therapies in [patients with] newly diagnosed multiple…
Dr Landgren on the Rationale for Assessing Daratumumab Plus KRd in Newly Identified Myeloma Read More